Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 5.9% - Time to Sell?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) shares dropped 5.9% during trading on Tuesday . The stock traded as low as $1.57 and last traded at $1.60. Approximately 119,589 shares changed hands during mid-day trading, an increase of 4% from the average daily volume of 114,703 shares. The stock had previously closed at $1.70.

Analyst Ratings Changes

Separately, The Goldman Sachs Group downgraded shares of Nautilus Biotechnology from a "neutral" rating to a "sell" rating and cut their price objective for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Trading Down 0.6 %

The company's fifty day moving average is $1.81 and its 200 day moving average is $2.31. The company has a market capitalization of $214.71 million, a P/E ratio of -3.05 and a beta of 1.21.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NAUT. SG Americas Securities LLC bought a new position in Nautilus Biotechnology in the 3rd quarter valued at $50,000. China Universal Asset Management Co. Ltd. boosted its holdings in Nautilus Biotechnology by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company's stock valued at $69,000 after purchasing an additional 9,404 shares during the period. The Manufacturers Life Insurance Company bought a new position in Nautilus Biotechnology in the 3rd quarter valued at $67,000. MetLife Investment Management LLC bought a new position in Nautilus Biotechnology in the 3rd quarter valued at $87,000. Finally, Wexford Capital LP boosted its holdings in Nautilus Biotechnology by 9.6% in the 3rd quarter. Wexford Capital LP now owns 228,350 shares of the company's stock valued at $651,000 after purchasing an additional 20,000 shares during the period. 50.71% of the stock is owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.